Palbociclib

Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.

Palbociclib-D8 is the 2H-labeled form of Palbociclib. Palbociclib (T1785) is an orally active CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM). Palbociclib (T1785) has anti-tumor activity and is used in research for estrogen receptor-positive and HER2-negative breast cancer.

Palbociclib-propargyl, a PROTAC ligand targeting the protein CDK6, connects to the CRBN ligand through a PEG linker to form PROTAC CP-10. CP-10 exhibits a potent DC50 value of 2.1 nM against CDK6[1].

Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Palbociclib Isethionate (PD 0332991 isethionate) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Verapamil hydrochloride (Verapamil HCl) is a calcium channel blocker that is a class IV anti-arrhythmia agent.

Verapamil (CP-16533-1) is a calcium channel blocker and an orally active and effective inhibitor of P-gp. Verapamil inhibits CYP3A4 and can be used in studies about the treatment of high blood pressure, heart arrhythmias, and angina research.

Palbociclib-C4-Boc is a target protein ligand-linker conjugate composed of the CDK4/6 ligand Palbociclib and a PROTAC linker, capable of recruiting E3 ligase. It is utilized in the synthesis of PROTACBSJ-03-204.

Palbociclib (PD 0332991) dihydrochloride is an orally active, selective inhibitor of CDK4 (IC50: 11 nM) and CDK6 (IC50: 16 nM), exhibiting anti-proliferative activity and inducing cell cycle arrest in HR-positive and HER2-negative breast cancers and hepatocellular carcinoma studies.

6-Desacetyl Palbociclib is a useful organic compound for research related to life sciences and the catalog number is T64486.

Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively. This compound demonstrates potent anti-proliferative effects and induces cell cycle arrest in cancer cells, applicable in research concerning HR-positive, HER2-negative breast cancer, and hepatocellular carcinoma [1] [3] [4].

N-Formyl Palbociclib-D8 is a deuterated compound of N-Formyl Palbociclib. N-Formyl Palbociclib has a CAS number of 2174002-16-3.

Palbociclib impurity 7 is an impurity of Palbociclib.

Palbociclib impurity 48 is an impurity associated with Palbociclib.

Palbociclib impurity 20 is an impurity of Palbociclib.

Palbociclib impurity 9 is an impurity associated with Palbociclib.

Palbociclib impurity 2 is a contaminant associated with Palbociclib.

Palbociclib Impurity 46 is a byproduct associated with the compound Palbociclib.

Palbociclib impurity 49 is an impurity associated with Palbociclib.

Palbociclib impurity 1 is a byproduct of the compound Palbociclib.

Palbociclib impurity 40 is a type of impurity found in Palbociclib.

Palbociclib-Succinic acid is a Palbociclib- derivative with a succinic acid linker. The carboxy group of Palbociclib-Succinic acid can be used to conjugate with other molecules such as peptides, proteins, or polymers. Palbociclib-Succinic acid is a useful

Palbociclib-SMCC is a Palbociclib derivative with a SMCC linker.

Palbociclib hydrochloride (pabociclib hydrochloride) is the salt form of Palbociclib, a selective and orally available CDK4 and CDK6 inhibitor with anti-tumor proliferative activity for use in breast and hepatocellular carcinoma.